This focused issue on Ovarian Cancer: State of the Art and Perspectives of Clinical Research is edited by Dr. Stergios Boussios, MD, MSc, PhD, MRCP, from Department of Medical Oncology, Medway NHS Foundation Trust, Kent, UK; and Dr. Nicholas Pavlidis, MD, PhD, FRCP, from University of Ioannina, Ioannina, Greece.
Dr. Stergios Boussios [MD, MSc, PhD, MRCP(London)] specialised in Internal Medicine in Komotini, Greece (2007-2009). Subsequently he trained in Medical Oncology at the Oncology Department of Ioannina University Hospital, Greece (2010-2013) where he gained experience in the diagnostic and therapeutic approach of solid tumours, working for Prof Nicholas Pavlidis. Currently, he serves as Consultant at the Department of Medical Oncology, Medway Maritime NHS Foundation Trust, Kent Oncology Center, UK where he is Research Lead in the Acute Oncology and CUP and has regular teaching duties at Medway Maritime Hospital. He is actively involved in translational research in cancer and is Principal Investigator at Medway Maritime NHS Foundation Trust in phase I-III studies. His research interests include individualisation of patient treatment and targeted therapies in gynaecological cancers, CUP, urological cancers, new drug development and cancer diagnosed in pregnancy.
Nicholas Pavlidis, MD, PhD, FRCP Edin (Hon), served as Senior Oncologist at the Cancer Institute in Athens before moving to the University of Ioannina where he is currently a Professor and Director of the Medical Oncology Department. He studied Medicine at the University of Athens. He did his bench research in the field of tumor immunology at the National Institutes of Health in Bethesda, USA. His clinical training in Medical Oncology was done at the Royal Marsden Hospital in London, U.K. Prof Pavlidis was secretary in the Early Clinical Trials Group of EORTC of which he is still an active member. He is a member of ESMO Steering Educational Committee, former Chairman of ESMO Guidelines Task Force and present Chairman of the ESMO Global Curriculum Task force. He is also member of ESMO Steering Committee for Rare Cancers. He is a member of the Scientific Committee of the European School of Oncology and Chairman in various educational activities.
Focused issue outline:
- Current Practices on Genetic Testing in Ovarian Cancer
- Ovarian Cancer Risk Assessment in the Era of Next-Generation Sequencing
- The Clinical Impact of Predictive Biomarkers in High-Grade Serous Ovarian Cancer
- DNA Damage Response: Beyond PARP Inhibition
- Notch signalling in ovarian angiogenesis
- Novel PARP inhibitors in ovarian cancer: Quo Vadis?
- Upfront debulking surgery for high-grade serous ovarian carcinoma: Current Evidence
- Interval debulking surgery for high-grade serous ovarian carcinoma: Current Evidence
- Robotic Surgery in Ovarian Cancer Patients: Is it Safe and Effective?
- Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: Cui Bono?
- Peritoneal Cancer of Unknown Primary Site: a piece of an intricate puzzle
- Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: Where do we stand and where are we going?
- Metformin and Ovarian Cancer: The evidence
- Endometriosis-associated Ovarian Carcinomas: Insights into Pathogenesis, Diagnostics, and Therapeutic Targets
- Malignant Germ Cell Tumour of the Ovary: Current Management and Promising Approaches
- Current and Future Immunotherapy Approaches in Ovarian Cancer
- International variations in ovarian cancer diagnosis and treatment: An Update